Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Christopher Lieu

Concepts (385)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colorectal Neoplasms
47
2024
746
8.890
Why?
Colonic Neoplasms
8
2024
242
2.700
Why?
Antineoplastic Combined Chemotherapy Protocols
21
2024
1559
2.260
Why?
Molecular Targeted Therapy
9
2019
385
2.030
Why?
Antineoplastic Agents
14
2021
2051
1.990
Why?
Biomarkers, Tumor
17
2025
1181
1.970
Why?
Rectal Neoplasms
7
2023
136
1.770
Why?
Antibodies, Monoclonal, Humanized
10
2024
755
1.750
Why?
Bevacizumab
5
2024
129
1.700
Why?
Benzimidazoles
3
2024
157
1.600
Why?
Neoplasms
13
2024
2464
1.270
Why?
Drug Resistance, Neoplasm
9
2024
749
1.230
Why?
Mutation
14
2024
3689
1.100
Why?
Age of Onset
9
2024
491
1.050
Why?
Gastrointestinal Neoplasms
2
2025
72
1.010
Why?
Immunotherapy
4
2022
587
0.940
Why?
Neuroendocrine Tumors
6
2024
97
0.920
Why?
Vascular Endothelial Growth Factor A
4
2020
500
0.900
Why?
Neoplasm Staging
12
2024
1290
0.860
Why?
Cetuximab
4
2023
93
0.840
Why?
Oncologists
1
2023
35
0.840
Why?
Microsatellite Instability
8
2024
37
0.830
Why?
Proto-Oncogene Proteins p21(ras)
4
2019
258
0.830
Why?
Proto-Oncogene Proteins B-raf
6
2024
214
0.800
Why?
Pancreatic Neoplasms
8
2024
875
0.790
Why?
Antibodies, Monoclonal
6
2023
1355
0.760
Why?
Humans
94
2025
128417
0.710
Why?
Pyrimidinones
2
2024
101
0.690
Why?
Pyridones
2
2024
159
0.640
Why?
Early Detection of Cancer
3
2024
369
0.620
Why?
Piperidines
2
2017
190
0.600
Why?
Colectomy
1
2019
93
0.600
Why?
Circulating Tumor DNA
3
2025
28
0.600
Why?
Cyclosporine
1
2018
169
0.580
Why?
Middle Aged
38
2024
30889
0.560
Why?
Terminology as Topic
1
2019
202
0.560
Why?
Disease-Free Survival
7
2023
647
0.560
Why?
Fluorouracil
6
2024
197
0.560
Why?
Azetidines
1
2017
40
0.550
Why?
Genetic Predisposition to Disease
4
2022
2264
0.550
Why?
Appendiceal Neoplasms
2
2020
26
0.530
Why?
Aged
29
2024
21953
0.500
Why?
Medical Oncology
5
2023
271
0.500
Why?
Adrenal Gland Neoplasms
3
2022
83
0.490
Why?
Wnt Signaling Pathway
2
2024
165
0.490
Why?
MAP Kinase Kinase Kinases
1
2015
71
0.480
Why?
Patient Rights
1
2015
11
0.480
Why?
Therapies, Investigational
1
2015
14
0.480
Why?
Precision Medicine
1
2019
384
0.470
Why?
Drug and Narcotic Control
1
2015
28
0.470
Why?
Chemotherapy, Adjuvant
5
2024
376
0.470
Why?
Adult
34
2024
35299
0.470
Why?
Healthcare Disparities
1
2021
579
0.470
Why?
Drugs, Investigational
1
2015
32
0.470
Why?
Neovascularization, Pathologic
2
2013
290
0.460
Why?
Adenocarcinoma
5
2023
888
0.440
Why?
Pyrazines
2
2018
86
0.420
Why?
Camptothecin
4
2024
106
0.420
Why?
Clinical Trials as Topic
4
2025
993
0.420
Why?
Drug Evaluation, Preclinical
1
2013
168
0.410
Why?
Immunoglobulin G
1
2017
843
0.410
Why?
Microsatellite Repeats
2
2024
161
0.410
Why?
Male
39
2024
62857
0.410
Why?
Drug Design
1
2013
154
0.400
Why?
Leucovorin
5
2024
68
0.400
Why?
ErbB Receptors
5
2017
601
0.390
Why?
Neoadjuvant Therapy
5
2023
381
0.380
Why?
Female
39
2024
68153
0.380
Why?
Terminal Care
1
2015
234
0.370
Why?
Neoplasm Metastasis
7
2022
608
0.370
Why?
Carcinoma, Signet Ring Cell
1
2011
9
0.370
Why?
Cell Transformation, Neoplastic
1
2013
325
0.360
Why?
Treatment Outcome
13
2024
10151
0.350
Why?
Carcinoma, Pancreatic Ductal
2
2024
265
0.350
Why?
Imidazoles
2
2024
226
0.350
Why?
Fibroblast Growth Factors
1
2011
170
0.340
Why?
Clinical Decision-Making
4
2024
304
0.330
Why?
Xenograft Model Antitumor Assays
6
2024
814
0.330
Why?
src-Family Kinases
1
2010
95
0.320
Why?
Patient Selection
3
2019
663
0.320
Why?
Stomach Neoplasms
3
2022
97
0.310
Why?
Disease Management
4
2021
587
0.300
Why?
Boronic Acids
1
2008
37
0.300
Why?
Janus Kinase 2
1
2008
32
0.290
Why?
Etoposide
1
2008
149
0.290
Why?
Carboplatin
1
2008
140
0.290
Why?
Myeloproliferative Disorders
1
2008
26
0.290
Why?
Health Services Accessibility
1
2015
896
0.290
Why?
Genomics
3
2022
715
0.280
Why?
Kaplan-Meier Estimate
6
2017
853
0.280
Why?
Organoplatinum Compounds
2
2024
40
0.280
Why?
Carcinoembryonic Antigen
2
2024
41
0.270
Why?
Cancer Survivors
2
2024
263
0.270
Why?
Pathology, Molecular
2
2017
25
0.270
Why?
Shock, Septic
1
2009
205
0.270
Why?
Pathology, Clinical
2
2017
36
0.270
Why?
Drug Administration Schedule
4
2019
751
0.260
Why?
ras Proteins
2
2017
145
0.250
Why?
Age Factors
5
2021
3103
0.240
Why?
Diagnosis, Differential
1
2009
1416
0.230
Why?
Aged, 80 and over
11
2024
7033
0.230
Why?
Oximes
1
2024
20
0.230
Why?
United States
13
2025
13830
0.230
Why?
CD3 Complex
1
2024
101
0.220
Why?
Young Adult
5
2024
12312
0.210
Why?
Antibodies, Bispecific
1
2024
49
0.210
Why?
Metastasectomy
1
2023
19
0.210
Why?
Signal Transduction
6
2018
4826
0.210
Why?
Trifluridine
1
2022
3
0.210
Why?
Clinical Trials, Phase II as Topic
2
2022
71
0.210
Why?
Ovarian Neoplasms
2
2020
488
0.200
Why?
Neoplasm Grading
2
2024
283
0.200
Why?
Surgical Oncology
1
2022
22
0.200
Why?
Clinical Trials, Phase III as Topic
2
2022
90
0.200
Why?
Empathy
1
2024
170
0.200
Why?
Disease Models, Animal
4
2021
3937
0.200
Why?
Genetic Testing
3
2022
428
0.190
Why?
Survival Rate
6
2023
1869
0.190
Why?
Membrane Proteins
3
2019
1105
0.190
Why?
Chemoradiotherapy, Adjuvant
2
2023
41
0.190
Why?
Incidence
6
2022
2616
0.190
Why?
Gene Regulatory Networks
1
2024
280
0.190
Why?
Artificial Intelligence
1
2024
244
0.190
Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
2022
33
0.190
Why?
Neoplasms, Multiple Primary
1
2022
54
0.190
Why?
DNA
1
2008
1390
0.180
Why?
Pheochromocytoma
1
2022
57
0.180
Why?
Meningioma
1
2022
81
0.180
Why?
Capecitabine
2
2022
46
0.180
Why?
Health Status Disparities
2
2020
254
0.180
Why?
Congresses as Topic
2
2019
212
0.180
Why?
Heterografts
1
2021
129
0.170
Why?
Practice Patterns, Physicians'
1
2009
1258
0.170
Why?
Deoxycytidine
2
2024
163
0.170
Why?
Immune System
1
2021
176
0.160
Why?
Adenomatous Polyposis Coli Protein
1
2019
20
0.160
Why?
Area Under Curve
2
2018
279
0.160
Why?
Smad4 Protein
1
2019
37
0.160
Why?
Cell Line, Tumor
4
2024
3184
0.160
Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
81
0.160
Why?
Consensus
2
2019
613
0.160
Why?
GTP Phosphohydrolases
1
2019
84
0.160
Why?
Retinal Vein
1
2019
13
0.160
Why?
Dose-Response Relationship, Drug
2
2017
1936
0.160
Why?
Prognosis
8
2023
3772
0.160
Why?
Tumor Suppressor Protein p53
2
2022
508
0.160
Why?
Cell-Free Nucleic Acids
1
2019
31
0.150
Why?
Disease Progression
4
2017
2602
0.150
Why?
B7-H1 Antigen
1
2020
189
0.150
Why?
Vasculitis
1
2019
59
0.150
Why?
Genes, ras
1
2018
98
0.150
Why?
DNA Mismatch Repair
3
2024
47
0.150
Why?
Proportional Hazards Models
3
2017
1196
0.150
Why?
Cohort Studies
6
2020
5388
0.150
Why?
Retinal Diseases
1
2019
86
0.150
Why?
Drug Combinations
2
2022
323
0.150
Why?
Risk Factors
6
2022
9704
0.150
Why?
Survivorship
1
2018
48
0.140
Why?
Neoplasm Transplantation
1
2018
258
0.140
Why?
Population Surveillance
1
2021
427
0.140
Why?
Liver Neoplasms
2
2024
633
0.140
Why?
Risk Assessment
2
2019
3232
0.140
Why?
Patient Advocacy
1
2018
74
0.140
Why?
Evidence-Based Medicine
2
2019
711
0.140
Why?
Acneiform Eruptions
1
2017
1
0.140
Why?
Asthenia
1
2017
2
0.140
Why?
Drug Eruptions
1
2017
25
0.140
Why?
Neoplasm Recurrence, Local
2
2023
958
0.140
Why?
Hypokalemia
1
2017
24
0.140
Why?
Esophageal Neoplasms
1
2021
293
0.140
Why?
Patient Compliance
1
2021
560
0.140
Why?
Histone Deacetylase Inhibitors
1
2019
207
0.140
Why?
Receptor, ErbB-3
1
2017
45
0.140
Why?
MAP Kinase Kinase 1
1
2017
76
0.140
Why?
Animals
10
2024
34479
0.140
Why?
Programmed Cell Death 1 Receptor
1
2019
228
0.130
Why?
Intercellular Signaling Peptides and Proteins
2
2015
371
0.130
Why?
Antineoplastic Agents, Immunological
1
2019
175
0.130
Why?
Digestive System Neoplasms
1
2016
8
0.130
Why?
Time Factors
2
2019
6482
0.130
Why?
Hospitals
1
2021
631
0.130
Why?
Biomarkers
3
2023
3880
0.130
Why?
Triple Negative Breast Neoplasms
1
2019
191
0.130
Why?
Insulin-Like Growth Factor I
1
2018
307
0.130
Why?
Edema
1
2016
125
0.130
Why?
Diabetic Neuropathies
1
2016
90
0.130
Why?
Retrospective Studies
9
2023
14454
0.130
Why?
Biliary Tract Neoplasms
1
2015
25
0.130
Why?
Databases, Factual
3
2017
1269
0.130
Why?
GPI-Linked Proteins
1
2016
67
0.120
Why?
Analgesics
1
2016
163
0.120
Why?
Delivery of Health Care, Integrated
1
2018
248
0.120
Why?
Patient Care Planning
1
2016
149
0.120
Why?
Device Approval
1
2015
21
0.120
Why?
Neuralgia
1
2016
119
0.120
Why?
Receptor, Notch1
1
2015
61
0.120
Why?
Immunoblotting
1
2015
300
0.120
Why?
Prevalence
1
2022
2547
0.120
Why?
Quality of Life
2
2024
2680
0.120
Why?
Pancreas
1
2017
304
0.120
Why?
Health Behavior
1
2020
741
0.120
Why?
Administration, Oral
1
2017
754
0.120
Why?
Adolescent
4
2024
20179
0.120
Why?
Gene Dosage
1
2015
142
0.120
Why?
Immunoconjugates
1
2016
101
0.110
Why?
Gene Expression Regulation
1
2024
2505
0.110
Why?
Drug Approval
1
2015
86
0.110
Why?
DNA Copy Number Variations
1
2015
169
0.110
Why?
Genetic Variation
1
2019
933
0.110
Why?
Quinazolines
1
2015
243
0.110
Why?
Phenotype
2
2021
3044
0.110
Why?
United States Food and Drug Administration
1
2015
199
0.110
Why?
Delivery of Health Care
1
2021
895
0.110
Why?
Lung Neoplasms
2
2024
2328
0.110
Why?
Proto-Oncogene Proteins
1
2017
634
0.110
Why?
beta Catenin
1
2015
219
0.110
Why?
Spinal Cord Injuries
1
2016
193
0.110
Why?
Oligonucleotide Array Sequence Analysis
1
2015
756
0.110
Why?
Randomized Controlled Trials as Topic
1
2019
1356
0.100
Why?
Registries
1
2021
1877
0.100
Why?
Patient-Centered Care
1
2018
501
0.100
Why?
National Cancer Institute (U.S.)
2
2025
43
0.100
Why?
Lymphocytes
1
2015
367
0.100
Why?
Protein Kinase Inhibitors
1
2018
872
0.100
Why?
Angiogenesis Inhibitors
1
2013
215
0.100
Why?
Risk
1
2014
853
0.100
Why?
Ligands
1
2013
614
0.090
Why?
Prospective Studies
3
2022
7036
0.090
Why?
Patient Care Team
1
2016
605
0.090
Why?
Mice
5
2024
16602
0.090
Why?
Neoplasm, Residual
2
2022
119
0.090
Why?
Protein-Tyrosine Kinases
1
2013
430
0.080
Why?
Mice, Nude
2
2024
682
0.080
Why?
Apoptosis
3
2022
2435
0.080
Why?
Streptococcaceae
1
2009
2
0.080
Why?
Transcriptome
1
2015
881
0.080
Why?
Neutrophils
1
2015
1193
0.080
Why?
Cytokines
2
2015
1983
0.080
Why?
Patient Satisfaction
1
2013
641
0.080
Why?
Clinical Medicine
1
2009
21
0.080
Why?
Chemoradiotherapy
2
2023
209
0.080
Why?
Myositis
1
2009
51
0.080
Why?
Sulindac
1
2008
15
0.080
Why?
Bortezomib
1
2008
45
0.080
Why?
Mutation Rate
2
2019
25
0.070
Why?
Taiwan
1
2008
19
0.070
Why?
Combined Modality Therapy
1
2011
1204
0.070
Why?
Maximum Tolerated Dose
1
2008
192
0.070
Why?
Nausea
1
2008
107
0.070
Why?
Neutropenia
1
2008
134
0.070
Why?
Immunoenzyme Techniques
1
2008
206
0.070
Why?
Multivariate Analysis
3
2017
1484
0.070
Why?
Fluphenazine
1
2007
5
0.070
Why?
Risperidone
1
2007
28
0.070
Why?
Nerve Fibers, Myelinated
1
2007
43
0.070
Why?
Drug Therapy, Combination
1
2010
1009
0.070
Why?
Anemia
1
2008
160
0.070
Why?
Food
1
2008
155
0.070
Why?
Exons
1
2008
338
0.070
Why?
Gastrectomy
2
2017
99
0.070
Why?
Fasting
1
2008
264
0.070
Why?
Thrombocytopenia
1
2008
181
0.070
Why?
Frontal Lobe
1
2007
153
0.060
Why?
Propensity Score
2
2017
264
0.060
Why?
Postoperative Complications
1
2017
2485
0.060
Why?
Antipsychotic Agents
1
2007
191
0.060
Why?
Polymerase Chain Reaction
1
2008
1020
0.060
Why?
Loneliness
1
2024
38
0.060
Why?
Survival Analysis
2
2017
1263
0.060
Why?
Delayed Diagnosis
1
2024
79
0.050
Why?
Oxidative Stress
1
2010
1176
0.050
Why?
Natural Language Processing
1
2024
94
0.050
Why?
Organoids
1
2024
104
0.050
Why?
Paclitaxel
1
2024
214
0.050
Why?
Cyclooxygenase 2 Inhibitors
1
2022
21
0.050
Why?
G2 Phase Cell Cycle Checkpoints
1
2022
45
0.050
Why?
Resilience, Psychological
1
2024
123
0.050
Why?
Endothelial Growth Factors
1
2022
51
0.050
Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
64
0.050
Why?
Gallium Radioisotopes
1
2022
14
0.050
Why?
Radioisotopes
1
2022
31
0.050
Why?
Receptors, Peptide
1
2022
17
0.050
Why?
Radionuclide Imaging
1
2022
123
0.050
Why?
Intestinal Neoplasms
1
2022
27
0.050
Why?
Positron Emission Tomography Computed Tomography
1
2022
84
0.050
Why?
Neoplastic Syndromes, Hereditary
1
2021
38
0.050
Why?
Radiopharmaceuticals
1
2022
166
0.050
Why?
Europe
1
2022
359
0.050
Why?
North America
1
2022
289
0.050
Why?
Surveys and Questionnaires
2
2024
5362
0.050
Why?
Chimerism
1
2021
29
0.050
Why?
Canada
1
2022
344
0.050
Why?
Preventive Medicine
1
2021
41
0.040
Why?
Lymphoid Tissue
1
2021
68
0.040
Why?
Lymphocyte Subsets
1
2021
85
0.040
Why?
Liquid Biopsy
1
2020
8
0.040
Why?
Positron-Emission Tomography
1
2022
283
0.040
Why?
Hyaluronic Acid
1
2022
211
0.040
Why?
Mice, SCID
1
2021
350
0.040
Why?
Geography
1
2020
186
0.040
Why?
Morbidity
1
2021
301
0.040
Why?
Receptor Protein-Tyrosine Kinases
1
2022
221
0.040
Why?
SEER Program
1
2020
206
0.040
Why?
Mice, Inbred NOD
1
2021
586
0.040
Why?
Spectrophotometry, Infrared
1
2019
53
0.040
Why?
Sulfonamides
1
2022
499
0.040
Why?
District of Columbia
1
2018
26
0.040
Why?
Karnofsky Performance Status
1
2018
38
0.040
Why?
Structure-Activity Relationship
1
2019
530
0.040
Why?
Colon
1
2020
248
0.040
Why?
Fluorescein Angiography
1
2019
143
0.040
Why?
Multimodal Imaging
1
2019
109
0.040
Why?
RNA
1
2024
880
0.040
Why?
Half-Life
1
2017
143
0.040
Why?
Melanoma
1
2024
752
0.030
Why?
Tomography, Optical Coherence
1
2019
187
0.030
Why?
American Medical Association
1
2017
16
0.030
Why?
Genome, Human
1
2019
391
0.030
Why?
Gene Expression Profiling
1
2024
1688
0.030
Why?
Reproducibility of Results
1
2024
3020
0.030
Why?
Delphi Technique
1
2018
221
0.030
Why?
Lymphocytes, Tumor-Infiltrating
1
2019
210
0.030
Why?
Genomic Instability
1
2017
47
0.030
Why?
Needles
1
2016
56
0.030
Why?
Cell Proliferation
1
2024
2344
0.030
Why?
Radiotherapy, Adjuvant
1
2017
209
0.030
Why?
Infusions, Intravenous
1
2017
385
0.030
Why?
Health Services Needs and Demand
1
2018
264
0.030
Why?
Radiotherapy, Intensity-Modulated
1
2017
128
0.030
Why?
Algorithms
1
2024
1618
0.030
Why?
Meta-Analysis as Topic
1
2017
169
0.030
Why?
Retreatment
1
2016
69
0.030
Why?
Molecular Diagnostic Techniques
1
2017
97
0.030
Why?
Incidental Findings
1
2016
79
0.030
Why?
Acute Disease
1
2019
964
0.030
Why?
DNA Mutational Analysis
1
2017
384
0.030
Why?
Platinum
1
2016
44
0.030
Why?
Jagged-1 Protein
1
2015
22
0.030
Why?
Serrate-Jagged Proteins
1
2015
27
0.030
Why?
Gene Frequency
1
2017
504
0.030
Why?
Neoplasm Invasiveness
1
2017
480
0.030
Why?
Hematopoietic Stem Cell Transplantation
1
2021
572
0.030
Why?
Radiography
2
2016
859
0.030
Why?
Gene Duplication
1
2015
67
0.030
Why?
Magnetic Resonance Imaging
1
2007
3376
0.030
Why?
Endoscopy, Digestive System
1
2016
122
0.030
Why?
Preoperative Care
1
2017
338
0.030
Why?
Tumor Microenvironment
1
2019
623
0.030
Why?
Practice Guidelines as Topic
1
2022
1478
0.030
Why?
Protein Isoforms
1
2016
378
0.030
Why?
Mice, Knockout
1
2021
2755
0.030
Why?
Leukocyte Count
1
2015
325
0.030
Why?
Analysis of Variance
1
2017
1269
0.030
Why?
Societies, Medical
1
2018
745
0.030
Why?
Calcium-Binding Proteins
1
2015
210
0.030
Why?
Ultraviolet Rays
1
2016
384
0.030
Why?
Protein Processing, Post-Translational
1
2016
449
0.030
Why?
Behavior, Animal
1
2016
484
0.030
Why?
CD8-Positive T-Lymphocytes
1
2019
846
0.030
Why?
Brain Neoplasms
1
2021
1163
0.030
Why?
Logistic Models
1
2017
1974
0.020
Why?
Skin
1
2016
718
0.020
Why?
Cross-Sectional Studies
1
2022
5039
0.020
Why?
Follow-Up Studies
1
2020
4892
0.020
Why?
Immunohistochemistry
1
2016
1664
0.020
Why?
Rats, Sprague-Dawley
1
2016
2239
0.020
Why?
Lung
1
2023
3743
0.020
Why?
Protein Binding
1
2016
2103
0.020
Why?
Angiogenesis Inducing Agents
1
2009
24
0.020
Why?
Rats
1
2016
5165
0.020
Why?
Glycogen Synthase Kinase 3 beta
1
2008
67
0.020
Why?
Glycogen Synthase Kinase 3
1
2008
79
0.020
Why?
Reference Standards
1
2008
168
0.020
Why?
Pharmacogenetics
1
2008
171
0.020
Why?
Breast Neoplasms
1
2019
2132
0.020
Why?
Chromatography, High Pressure Liquid
1
2008
475
0.020
Why?
Mice, Inbred C57BL
1
2016
5272
0.020
Why?
Infusions, Intra-Arterial
1
1986
54
0.020
Why?
Hepatic Artery
1
1986
58
0.020
Why?
Tomography, X-Ray Computed
1
2016
2523
0.020
Why?
Predictive Value of Tests
1
2011
1935
0.020
Why?
Tandem Mass Spectrometry
1
2008
449
0.020
Why?
Reference Values
1
2007
776
0.020
Why?
Image Processing, Computer-Assisted
1
2007
735
0.010
Why?
Longitudinal Studies
1
2007
2710
0.010
Why?
Lieu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)